Partnership Opportunities
Through extensive research with industry leaders from MD Anderson, Gilead Sciences, Onchilles Pharma, DEM Biopharma, NGM Biopharma and many more within the innate immune cell field, it is clear that understanding the full extent to which we can preclinically for better efficacy in clinic, understanding complications within the TME and deciding effective biomarkers and endpoints are great challenges, and further to that, the capacity of the service providers available to them. These major bottlenecks, with high pressured timelines in the race to deliver safe and effective therapeutic products to patients in need.
If you are a contract service or technology provider with the analytical experience and specific technologies to meet this exploding markets’ demands, then the Tumor Myeloid Targeting Therapies Summit will provide a platform for you to showcase your solutions to a niche audience of experts from the field.
Why Partner:
Meet Senior Decision Makers: Our meeting will unite everyone from CEOs, CSOs, VPs, Directors to technical leaders in discovery and early R&D, creating a niche environment so you can network directly with the most senior decision makers in the industry
Educate the Industry: Secure a speaking position to explain how your solutions can directly support potential clients who are actively seeking new solutions to optimize drug development inefficiencies
Gain Brand Visibility: Broaden your company’s exposure by presenting in front of experts from Novartis, Amgen, Carisma Therapeutics, AstraZeneca, Gilead Sciences and many more
Attendance by Company Type
Delegate Seniority Breakdown
